埃博拉出血热是由埃博拉病毒感染导致的急性出血性传染病,也是一种传染性强、传播速度快并且致死率高的疾病,其致死率从25%到90%不等,被世界卫生组织列为对人类危害最严重的烈性病之一。虽然人们对埃博拉出血热的治疗进行了一系列的研究,但是目前没有任何认证的药物或者疫苗来对抗埃博拉病毒。因此新型抑制剂的研发需求迫切。. 最近我们解析了埃博拉病毒囊膜蛋白GP结合其受体NPC1的分子机制，为埃博拉药物设计提供了新的靶标。本课题主要利用生物化学、分子生物学、结构生物学和病毒学等手段，靶向埃博拉病毒囊膜蛋白GP与NPC1互作的特异性位点，设计多肽抑制剂、合成小分子抑制剂、筛选微生物天然产物抑制剂来阻断GP与NPC1的结合，进而阻断埃博拉病毒的侵染。本课题重点从上述三方面来研究埃博拉病毒抑制剂的设计与改造，阐明这些新型抑制剂和埃博拉病毒囊膜蛋白GP的作用机制，为抗埃博拉病毒感染提供新型候选药物。

Ebola hemorrhagic fever (EHF) is a viral hemorrhagic fever of humans and other primates caused by ebola viruses, which has been listed as a Risk Group 4 Pathogen by the World Health Organization due to its high mortality rate (from 25% to 90%). Heretofore, there are no any licensed drugs or vaccines against the Ebola virus, therefore it is urgent to develop new drugs. . Our previous study has shown Ebola entry using the endosome pathway, which has paved way to block the entry of Ebola. In this study, we will focus on designing the specific peptide and chemical inhibitor, and screening natural products from microbe based on the molecular mechanism of Ebola entry(i.e. 3D structure of Ebola GP and NPC1 complex). We will combine the biochemical, molecular, structural and viral approaches to elucidate the mechanism of the candidate drugs to block Ebola entry. These studies will shed light on the therapeutic strategy of anti-Ebola.